Drugs / RSV/ΔNS2/Δ1313/I1314L
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04491877 | Sep 2020 → Apr 2023 | respiratory syncytial virus infectious disease | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RSV/ΔNS2/Δ1313/I1314L | “RSV/ΔNS2/Δ1313/I1314L (RSVt) (Sanofi) is a candidate live-attenuated intranasal respiratory syncytial virus (RSV) vaccine for infants and toddlers.” PMID 40856556 ↗ Aug 2025 |
| Known as | RSVt | “RSV/ΔNS2/Δ1313/I1314L (RSVt) (Sanofi) is a candidate live-attenuated intranasal respiratory syncytial virus (RSV) vaccine for infants and toddlers.” PMID 40856556 ↗ Aug 2025 |
| Modality | Vaccine | “candidate live-attenuated intranasal respiratory syncytial virus (RSV) vaccine” PMID 40856556 ↗ Aug 2025 |
| Route | Intranasal | “Route of administration: Intranasal” NCT04491877 ↗ |